Expertise

Pricentric Team

Pricentric One by EVERSANA is a powerful competitor intelligence tool that provides near real-time updates to drug price (list / net), reimbursement, tender and cost of treatment information at the indication level.

Our team of experts track real time pricing changes across 87+ markets and 200+ therapeutic areas and develop county profiles to inform global pricing and market access strategies for our pharma clients.

Articles by Pricentric Team

Italy Tackles HTA, Pricing and Reimbursement Reforms

In July, new legislation set to overhaul the way pharmaceuticals are priced in Italy was finally implemented, following an announcement that dates all the way back to August 2019. The provision, which was signed by then Ministers Giulia Grillo (Health) and Giovanni Tria (Economy), has rolled out new criteria and methods by which the Italian […]

At the COVID-19 Finish Line, How Do We Price The Winning Vaccine?

As of August 21, 2020, there were more than 165 potential vaccine candidates in development for the novel coronavirus. While some are still in preclinical stages, a handful are quickly making their way toward regulatory approval, meaning that pricing is starting to become an urgent reality. The first safety trials in humans started as early […]

Is BeNeLuxA Equipped for a Zolgensma Assessment?

The BeNeLuxA initiative is set to take on Zolgensma (onasemnogene abeparvovec), an innovative gene therapy for children under two years old with spinal muscular atrophy (SMA), which was granted conditional approval for use in Europe in May. Belgium, Ireland, and the Netherlands will undertake a joint health technology assessment (HTA) of Zolgensma as part of […]

Pricentric ONE Newsletter | June 2020

Good news, this month’s issue of the Pricentric Newsletter is now available for download. Fill out the form below to download the Newsletter!

What Canada’s IRP Changes Could Mean for the Industry

Last August, Canada’s Patented Medicine Prices Review Board (PMPRB) announced a set of amendments for its regulatory measures, in a bid to strengthen and modernize the country’s pricing framework for patented drugs. Following the initial proposal of the alterations, the PMPRB released its new draft guidelines in November 2019 and launched a 60-day consultation period […]

Pricentric ONE Newsletter | May 2020

Good news, this month’s issue of the Pricentric Newsletter is now available for download. Fill out the form below to download the Newsletter!

Pricentric ONE Newsletter | April 2020

Good news, this month’s issue of the Pricentric Newsletter is now available for download. Fill out the form below to download the Newsletter!

Is ICER Increasing Influence in the U.S. Over Time?

Recent high-profile product launches have reignited the debate on healthcare costs in the US. The Institute for Clinical and Economic Review (ICER) is an independent research organization that determines value-based price benchmarks. In a recent study, Dr. Stino, Product Manager, examined recent high-profile launches to understand the interaction between ICER value-based price benchmarks and actual […]

How do we pay for a cure?

Setting drug prices is a high-stakes endeavor, and that is especially true for the latest round of gene and curative products coming to market in Europe.  Drugmakers need to consider several factors that can help them set their product prices appropriately, including the risk of recurrence/relapse, differences in efficacy among cures, and comparators, including full […]

‘Tis the season for pharma in China, as the government expedites uptake of new urgently needed drugs

PRICENTRIC BRIEF: Universal health insurance coverage for 1.3 billion people means China must increase uptake of “clinically urgently needed new drugs” already approved in the US, EU, and Japan Mostly oncology products are being imported, along with HIV/AIDS medicines Pharma is agreeing to steep discounts to be reimbursed on China’s national drug lists THE DETAILS […]

“Who wants the biggest slice of the biosimilar pie?”: The Humira biosimilar wave in Europe

PRICENTRIC BRIEF: Biosimilar competition in Europe has brought about discounts to AbbVie’s blockbuster immunosuppressant drug Humira upwards of 80% during tendering Overall, biosimilar uptake has increased in Europe because biologic “copycats” are cheaper, but full faith in these products is still required from physicians and patients In the US, Coherus struck preemptively with a 33% […]

Interested in scheduling a meeting or speaking event?

Contact Us

  • This field is for validation purposes and should be left unchanged.